Calabrese and his colleagues have also made significant efforts to refine the definition and classification of hormesis: an adaptive response of biological systems to low-intensity stressors, characterized by a biphasic dose-response curve with a stimulatory zone (typically 0.1-10 times the No-Observed-Adverse-Effect Level, NOAEL) and an inhibitory zone 7
Hormone profiles sometimes shifted
Some patients measured incorrect doses themselves
Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Safety Protocols: Monitoring Kidney Function During Treatment Slinic operates under a rigorous, safety-first protocol designed specifically for high-risk renal patients
